Anokion scientists have successfully applied the company’s proprietary erythrocyte-binding technology to induce humoral immune tolerance towards a highly foreign therapeutic drug in a pre-clinical setting. Asparaginase, an E. coli enzyme used to treat acute lymphoblastic leukemia, was engineered for erythrocyte binding and was demonstrated to reduce anti-drug antibody responses over 1,000-fold in mice. Additionally, the engineered asparaginase induced lasting immune tolerance which enabled follow-on treatment with the wild-type drug. The results were recently published in the peer-reviewed journal Science Advances.
Toggle navigation